PL2470199T3 - Enzymatyczna terapia zastępcza ze zwiększaniem dawki do leczenia niedoboru kwaśnej sfingomielinazy - Google Patents

Enzymatyczna terapia zastępcza ze zwiększaniem dawki do leczenia niedoboru kwaśnej sfingomielinazy

Info

Publication number
PL2470199T3
PL2470199T3 PL10812683T PL10812683T PL2470199T3 PL 2470199 T3 PL2470199 T3 PL 2470199T3 PL 10812683 T PL10812683 T PL 10812683T PL 10812683 T PL10812683 T PL 10812683T PL 2470199 T3 PL2470199 T3 PL 2470199T3
Authority
PL
Poland
Prior art keywords
replacement therapy
dose escalation
enzyme replacement
acid sphingomyelinase
treating acid
Prior art date
Application number
PL10812683T
Other languages
English (en)
Inventor
Edward H Schuchman
Robert J Desnick
Gerald F Cox
Laura P Andrews
James M Murray
Original Assignee
Icahn School Med Mount Sinai
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43625265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2470199(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Icahn School Med Mount Sinai, Genzyme Corp filed Critical Icahn School Med Mount Sinai
Publication of PL2470199T3 publication Critical patent/PL2470199T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Dermatology (AREA)
PL10812683T 2009-08-28 2010-08-28 Enzymatyczna terapia zastępcza ze zwiększaniem dawki do leczenia niedoboru kwaśnej sfingomielinazy PL2470199T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23811309P 2009-08-28 2009-08-28
EP10812683.0A EP2470199B1 (en) 2009-08-28 2010-08-28 Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
PCT/US2010/047057 WO2011025996A2 (en) 2009-08-28 2010-08-28 Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency

Publications (1)

Publication Number Publication Date
PL2470199T3 true PL2470199T3 (pl) 2019-11-29

Family

ID=43625265

Family Applications (3)

Application Number Title Priority Date Filing Date
PL21200695.1T PL3998078T3 (pl) 2009-08-28 2010-08-28 Enzymatyczna terapia zastępcza ze zwiększaniem dawki w leczeniu niedoboru kwaśnej sfingomielinazy
PL18199358T PL3482767T3 (pl) 2009-08-28 2010-08-28 Enzymatyczna terapia zastępcza ze zwiększaniem dawki do leczenia niedoboru kwaśnej sfingomielinazy
PL10812683T PL2470199T3 (pl) 2009-08-28 2010-08-28 Enzymatyczna terapia zastępcza ze zwiększaniem dawki do leczenia niedoboru kwaśnej sfingomielinazy

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL21200695.1T PL3998078T3 (pl) 2009-08-28 2010-08-28 Enzymatyczna terapia zastępcza ze zwiększaniem dawki w leczeniu niedoboru kwaśnej sfingomielinazy
PL18199358T PL3482767T3 (pl) 2009-08-28 2010-08-28 Enzymatyczna terapia zastępcza ze zwiększaniem dawki do leczenia niedoboru kwaśnej sfingomielinazy

Country Status (30)

Country Link
US (9) US8349319B2 (pl)
EP (4) EP3998078B1 (pl)
JP (8) JP5955219B2 (pl)
KR (6) KR102094253B1 (pl)
CN (3) CN106047835A (pl)
AU (6) AU2010286550B2 (pl)
BR (1) BR112012004377A2 (pl)
CA (1) CA2773133A1 (pl)
CL (1) CL2012000495A1 (pl)
CY (1) CY1122128T1 (pl)
DK (3) DK3998078T3 (pl)
ES (3) ES2902229T3 (pl)
FI (2) FI3998078T3 (pl)
FR (1) FR22C1062I2 (pl)
HR (3) HRP20191385T1 (pl)
HU (3) HUE046598T2 (pl)
IL (4) IL300625B2 (pl)
LT (4) LT3998078T (pl)
LU (1) LUC00288I2 (pl)
MX (2) MX392330B (pl)
NL (1) NL301211I2 (pl)
NO (1) NO2022054I1 (pl)
PL (3) PL3998078T3 (pl)
PT (3) PT3482767T (pl)
RU (2) RU2569744C2 (pl)
SI (3) SI2470199T1 (pl)
SM (1) SMT202500432T1 (pl)
TR (1) TR201911293T4 (pl)
WO (1) WO2011025996A2 (pl)
ZA (2) ZA201201435B (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889127B2 (en) 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
US20080228056A1 (en) 2007-03-13 2008-09-18 Michael Blomquist Basal rate testing using frequent blood glucose input
US7751907B2 (en) 2007-05-24 2010-07-06 Smiths Medical Asd, Inc. Expert system for insulin pump therapy
US8221345B2 (en) 2007-05-30 2012-07-17 Smiths Medical Asd, Inc. Insulin pump based expert system
ES2635726T3 (es) 2007-06-06 2017-10-04 Genzyme Corporation Terapia génica para enfermedades de almacenamiento lisosómico
CN106047835A (zh) * 2009-08-28 2016-10-26 西奈山医学院 用于治疗酸性鞘磷脂酶缺乏的剂量递增酶替代疗法
US8882701B2 (en) 2009-12-04 2014-11-11 Smiths Medical Asd, Inc. Advanced step therapy delivery for an ambulatory infusion pump and system
JP2013528379A (ja) 2010-05-21 2013-07-11 オームクス コーポレーション Ｐｓａ酵素活性アッセイによる癌の検出
CN103917094B (zh) 2011-03-18 2016-11-09 建新公司 葡萄糖基神经酰胺合酶抑制剂
HUE051021T2 (hu) 2011-09-07 2021-01-28 Sinai School Medicine Ceramidáz és sejtek differenciálódása
WO2013072060A2 (en) 2011-11-15 2013-05-23 Centogene Gmbh Method for the diagnosis of niemann-pick disease
ES2897825T3 (es) 2012-06-01 2022-03-02 Icahn School Med Mount Sinai Niveles de ceramida en el tratamiento y prevención de infecciones
JOP20130273B1 (ar) 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
PL2968479T3 (pl) 2013-03-14 2019-10-31 Icahn School Med Mount Sinai Kompozycje terapeutyczne ceramidazy kwasowej i sposoby ich wytwarzania i stosowania
JO3713B1 (ar) 2013-03-15 2021-01-31 Genzyme Corp أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
WO2014183873A1 (en) * 2013-05-14 2014-11-20 Centogene Ag Method for the diagnosis of niemann-pick disease
KR102228367B1 (ko) * 2013-06-07 2021-03-16 젠자임 코포레이션 산 스핑고미엘리나제 장애에 대한 마커 및 이의 용도
JP6984854B2 (ja) * 2015-10-08 2021-12-22 国立大学法人千葉大学 ニーマン・ピック病ｃ型を予防または治療するための医薬組成物
US10569016B2 (en) 2015-12-29 2020-02-25 Tandem Diabetes Care, Inc. System and method for switching between closed loop and open loop control of an ambulatory infusion pump
JP7216075B2 (ja) * 2017-08-24 2023-01-31 サノフイ 酸性スフィンゴミエリナーゼ欠損症患者における骨状態異常の処置
FR3070383B1 (fr) 2017-08-31 2021-08-20 Solable Appareil de traitement d'eau
PE20210347A1 (es) 2017-10-02 2021-02-25 Denali Therapeutics Inc Proteinas de fusion que comprenden enzimas de terapia de reemplazo de enzimas
UY38238A (es) 2018-05-25 2019-12-31 Genzyme Corp Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida
PL3920912T3 (pl) 2019-02-04 2025-11-12 Genzyme Corporation Leczenie ciliopatii przy użyciu inhibitorów syntazy glukozyloceramidowej (gcs)
AU2021215396B2 (en) 2020-02-03 2026-02-19 Genzyme Corporation Methods for treating neurological symptoms associated with lysosomal storage diseases
US11857512B2 (en) 2020-07-24 2024-01-02 Genzyme Corporation Pharmaceutical compositions comprising venglustat

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082781A (en) * 1976-06-04 1978-04-04 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of 2-alkanoylamino-4-nitrophenyl phosphorylcholine-hydroxide
US4039388A (en) 1976-06-04 1977-08-02 The United States Of America As Represented By The Government Diagnostic test for Niemann-Pick disease
IL74761A0 (en) 1984-04-13 1985-06-30 Hughes Howard Med Inst Human phenylalanine hydroxylase cdna clones,their production and their use in diagnosing classical phenylketonuria
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4863195A (en) * 1987-10-02 1989-09-05 Capozzola Carl A Identification tag
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
US5773278A (en) * 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
US5484719A (en) 1991-08-26 1996-01-16 Edible Vaccines, Inc. Vaccines produced and administered through edible plants
US6034298A (en) 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
US5612487A (en) 1991-08-26 1997-03-18 Edible Vaccines, Inc. Anti-viral vaccines expressed in plants
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5716614A (en) 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
EP0865499B1 (en) 1995-09-14 2009-03-18 Virginia Tech Intellectual Properties, Inc. Production of lysosomal enzymes in plant-based expression systems
JP2820106B2 (ja) 1996-02-29 1998-11-05 日本電気株式会社 トラヒックシェーパ装置
US20050032211A1 (en) 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
IL155588A0 (en) 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
BR9916522A (pt) 1998-12-23 2002-12-24 Thompson Boyce Plant Res Vetor de expressão de plantas, célula, semente vegetal, polinucleotìdeo, composição imunogênica, métodos para eliciar uma rsposta imune em mamìfero e para isolar polipeptìdeo, e, planta ou célula vegetal transgênicas
US6642038B1 (en) 1999-09-14 2003-11-04 Genzyme Glycobiology Research Institute, Inc. GlcNAc phosphotransferase of the lysosomal targeting pathway
US6770799B2 (en) 2000-03-17 2004-08-03 Thompson Boyce Plant Res Expression of recombinant human acetylcholinesterase in transgenic plants
AU2001269923A1 (en) * 2000-06-19 2002-01-02 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
AR034413A1 (es) 2000-08-25 2004-02-25 Nestor Abel Chamoles Metodo para determinar la actividad de las enzimas lisosomales
US7723296B2 (en) * 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US7001994B2 (en) * 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
ES2300439T3 (es) 2001-04-30 2008-06-16 Zystor Therapeutics , Inc. Reconocimiento subcelular de proteinas terapeuticas.
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
IES20011101A2 (en) * 2001-12-21 2003-06-25 Japkinstill Services Ltd A Bi-directional Messaging System
WO2003086452A2 (en) * 2002-04-05 2003-10-23 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy
US7585518B2 (en) 2002-11-19 2009-09-08 Kimberly-Clark Worldwide, Inc. Products and methods for maintaining or increasing ceramide levels in skin
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US7951557B2 (en) 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
JP2007518396A (ja) * 2003-06-12 2007-07-12 ジェンザイム・コーポレーション 増加した活性を有する修飾されたヒト酸性スフィンゴミエリナーゼおよびその製造方法
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) * 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
CA2546863A1 (en) 2003-11-25 2005-06-09 Mount Sinai School Of Medicine Of New York University Chaperone-based therapy for niemann-pick disease
EP1799813B1 (en) 2004-10-13 2010-05-19 Metabogal Ltd. System and method for production of antibodies in plant cell culture
US7615224B2 (en) 2004-12-02 2009-11-10 Women's And Children's Hospital Multiplex-bead complex for determination of lysosomal storage disorders
CA2634042A1 (en) 2005-12-15 2007-07-12 The Research Foundation Of State University Of New York Enzymatic methods for measuring plasma and tissue sphingomylelin and phosphatidylcholine
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
CA2641070C (en) 2006-02-06 2017-01-03 Ramot At Tel-Aviv University Ltd. Enzyme replacement therapy for treating lysosomal storage diseases
HUE040490T2 (hu) 2006-02-09 2019-03-28 Genzyme Corp Lassú intraventrikuláris szállítás
AU2007215080A1 (en) 2006-02-13 2007-08-23 Fraunhofer Usa, Inc. Influenza antigens, vaccine compositions, and related methods
JP5302189B2 (ja) 2007-04-27 2013-10-02 長瀬産業株式会社 スフィンゴミエリナーゼ
EP2323652A2 (en) 2008-08-06 2011-05-25 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
HUE044381T2 (hu) 2008-12-16 2019-10-28 Genzyme Corp Szintetikus intermedierek oligoszacharid-fehérje konjugátumok elõállításához
CN106047835A (zh) * 2009-08-28 2016-10-26 西奈山医学院 用于治疗酸性鞘磷脂酶缺乏的剂量递增酶替代疗法
US9155784B2 (en) * 2011-06-20 2015-10-13 Icahn School Of Medicine At Mount Sinai Anti-TNF-α therapy for the mucopolysaccharidoses and other lysosomal disorders
KR102228367B1 (ko) * 2013-06-07 2021-03-16 젠자임 코포레이션 산 스핑고미엘리나제 장애에 대한 마커 및 이의 용도
JP7216075B2 (ja) * 2017-08-24 2023-01-31 サノフイ 酸性スフィンゴミエリナーゼ欠損症患者における骨状態異常の処置

Also Published As

Publication number Publication date
EP3482767A1 (en) 2019-05-15
AU2018204156B2 (en) 2020-07-16
HRP20191385T1 (hr) 2019-11-01
US20210077593A1 (en) 2021-03-18
PT2470199T (pt) 2019-08-07
US20190151419A1 (en) 2019-05-23
US20160120957A1 (en) 2016-05-05
AU2024201085B2 (en) 2025-04-24
US10188705B2 (en) 2019-01-29
ES2902229T3 (es) 2022-03-25
IL300625B1 (en) 2024-09-01
AU2025205539A1 (en) 2025-08-07
DK3998078T3 (da) 2025-11-17
KR20210107153A (ko) 2021-08-31
HUE057440T2 (hu) 2022-05-28
US8709408B2 (en) 2014-04-29
KR20250171458A (ko) 2025-12-08
JP2013502933A (ja) 2013-01-31
PL3998078T3 (pl) 2026-02-16
FR22C1062I1 (fr) 2023-02-03
SI2470199T1 (sl) 2019-11-29
AU2016216625B2 (en) 2018-07-05
HRP20251310T1 (hr) 2026-01-02
JP2025038063A (ja) 2025-03-18
EP3482767B1 (en) 2021-10-06
LTC3482767I2 (pl) 2024-03-25
US20180055916A1 (en) 2018-03-01
KR102094253B1 (ko) 2020-03-31
TR201911293T4 (tr) 2019-08-21
PL3482767T3 (pl) 2022-02-14
JP2022003065A (ja) 2022-01-11
US8658162B2 (en) 2014-02-25
ZA201601362B (en) 2017-05-31
IL300625B2 (en) 2025-01-01
HRP20211992T1 (hr) 2022-04-01
US8349319B2 (en) 2013-01-08
JP6251307B2 (ja) 2017-12-20
EP3998078B1 (en) 2025-10-01
CY1122128T1 (el) 2020-11-25
JP2023012499A (ja) 2023-01-25
MX356873B (es) 2018-06-18
IL266915B1 (en) 2023-03-01
JP7167281B2 (ja) 2022-11-08
DK3482767T3 (da) 2021-12-20
LT2470199T (lt) 2019-10-10
SI3998078T1 (sl) 2026-02-27
IL266915A (en) 2019-07-31
RU2020128994A (ru) 2022-03-02
WO2011025996A3 (en) 2012-03-15
NL301211I1 (nl) 2022-12-28
PT3998078T (pt) 2025-11-07
AU2024201085A1 (en) 2024-03-07
SMT202500432T1 (it) 2026-01-12
JP2024026214A (ja) 2024-02-28
EP2470199B1 (en) 2019-05-22
ES2738859T3 (es) 2020-01-27
US20140335070A1 (en) 2014-11-13
JP6952810B2 (ja) 2021-10-20
AU2010286550A1 (en) 2012-03-15
BR112012004377A2 (pt) 2017-12-12
IL314807A (en) 2024-10-01
RU2569744C2 (ru) 2015-11-27
LT3482767T (lt) 2022-01-10
AU2020256322B2 (en) 2024-02-29
FI3998078T3 (fi) 2025-12-04
KR102608551B1 (ko) 2023-12-04
IL300625A (en) 2023-04-01
EP2470199A2 (en) 2012-07-04
EP4681775A3 (en) 2026-04-01
PT3482767T (pt) 2021-12-29
IL218324A0 (en) 2012-04-30
RU2015145255A3 (pl) 2019-08-12
DK2470199T3 (da) 2019-08-05
IL266915B2 (en) 2023-07-01
KR102608546B1 (ko) 2023-12-04
LT3998078T (lt) 2025-12-29
SI3482767T1 (sl) 2022-03-31
KR102893390B1 (ko) 2025-11-28
CL2012000495A1 (es) 2014-02-07
CA2773133A1 (en) 2011-03-03
EP4681775A2 (en) 2026-01-21
MX2012002449A (es) 2012-03-14
JP2016153408A (ja) 2016-08-25
US9655954B2 (en) 2017-05-23
NL301211I2 (nl) 2023-02-02
RU2731616C2 (ru) 2020-09-07
AU2018204156A1 (en) 2018-06-28
IL218324B (en) 2019-05-30
US20110052559A1 (en) 2011-03-03
FR22C1062I2 (fr) 2023-12-29
EP2470199A4 (en) 2013-03-27
HUE046598T2 (hu) 2020-03-30
RU2012111823A (ru) 2013-10-10
JP5955219B2 (ja) 2016-07-20
US20130078231A1 (en) 2013-03-28
KR20120081077A (ko) 2012-07-18
US20130078230A1 (en) 2013-03-28
JP2018076322A (ja) 2018-05-17
ES3052684T3 (en) 2026-01-13
ZA201201435B (en) 2020-05-27
NO2022054I1 (no) 2022-12-01
KR20200034828A (ko) 2020-03-31
MX392330B (es) 2025-03-11
WO2011025996A2 (en) 2011-03-03
AU2020256322A1 (en) 2020-11-12
KR20220104271A (ko) 2022-07-26
US9114139B2 (en) 2015-08-25
US20220305091A1 (en) 2022-09-29
CN106047835A (zh) 2016-10-26
RU2015145255A (ru) 2019-01-11
EP3998078A1 (en) 2022-05-18
FIC20220051I1 (fi) 2022-12-20
AU2010286550B2 (en) 2016-05-19
HUS2200050I1 (hu) 2022-12-28
JP7605949B2 (ja) 2024-12-24
JP7395693B2 (ja) 2023-12-11
JP2020090513A (ja) 2020-06-11
CN102596232A (zh) 2012-07-18
KR20230164773A (ko) 2023-12-04
CN105999238A (zh) 2016-10-12
LUC00288I2 (pl) 2025-05-12
AU2016216625A1 (en) 2016-09-15
WO2011025996A9 (en) 2011-08-25

Similar Documents

Publication Publication Date Title
HUS2200050I1 (hu) Dóziseszkalációs enzim helyettesítõ terápia savas szfingomielináz elégtelenség kezelésére
EP2308493A4 (en) ENHANCING OR THERAPEUTIC AGENT FOR DYSLIPIDEMIA
IL275350B (en) Treatment of neoplastic diseases
IL253293A0 (en) Desferrioxamine complexes of metals for the treatment of diseases related to the immune system
SG10201507199UA (en) Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
HUE043235T2 (hu) Terápiás kezelések tüdõbetegségekhez
EP2675472A4 (en) METHOD FOR THE TREATMENT OF LACK OF LYSOSOMAL SAURER LIPASE
PL2473172T3 (pl) Kompozycje bisfosfonianowe i sposoby do leczenia niewydolności serca
ZA201301279B (en) Preventive or therapeutic agent for fibrosis
ZA201009063B (en) Diaryl ureas for treating heart failure
IL216491A0 (en) Combination therapy for the treatment of multiple myeloma
EP2604264A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF VIRUS DISEASES
ZA201201894B (en) Pharmaceutical combination for treating tumor
GB0909239D0 (en) Targeted gene therapy
IL218160A0 (en) Desferrioxamine-metal complexes for the treatment of immune-related disorders